MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

AbCellera Biologics Inc

Chiusa

SettoreSettore sanitario

5.97 0.34

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.9

Massimo

6.19

Metriche Chiave

By Trading Economics

Entrata

11M

-35M

Vendite

13M

17M

Margine di Profitto

-203.272

Dipendenti

596

EBITDA

769K

-39M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+54.36% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

160M

1.5B

Apertura precedente

5.63

Chiusura precedente

5.97

Notizie sul Sentiment di mercato

By Acuity

59%

41%

318 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

AbCellera Biologics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 ott 2025, 23:30 UTC

Azioni calde

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 ott 2025, 21:21 UTC

Utili

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 ott 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 ott 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 ott 2025, 23:39 UTC

Discorsi di Mercato

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 ott 2025, 23:00 UTC

Discorsi di Mercato

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 ott 2025, 21:17 UTC

Acquisizioni, Fusioni, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 ott 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

2 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 ott 2025, 20:49 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 ott 2025, 20:00 UTC

Acquisizioni, Fusioni, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 ott 2025, 19:20 UTC

Discorsi di Mercato

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 ott 2025, 19:10 UTC

Discorsi di Mercato

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 ott 2025, 19:04 UTC

Discorsi di Mercato

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 ott 2025, 18:43 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Confronto tra pari

Modifica del prezzo

AbCellera Biologics Inc Previsione

Obiettivo di Prezzo

By TipRanks

54.36% in crescita

Previsioni per 12 mesi

Media 9.2 USD  54.36%

Alto 17 USD

Basso 5 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AbCellera Biologics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.99 / 2.635Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

318 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat